难治性急性移植物抗宿主病:超越糖皮质激素难治性的新工作定义
该文针对芦可替尼获批后如何界定对芦可替尼难治与依赖的患者群体,提出芦可替尼难治性急性GVHD的工作定义,包括进展、缺乏改善、失去反应三种情形,并给出临床指征和 eligibility 标准。
要点
- 芦可替尼难治性急性GVHD定义为治疗5-10天后进展、≥14天无改善或初始改善后失去反应。
- 出现≥3级治疗相关不良事件且停药7天未缓解的持续GVHD表现可作为追加治疗的临床指征。
- 芦可替尼治疗后第28天未达完全缓解或极好部分缓解可考虑作为 eligibility 标准。
核心结论
- 作者提出芦可替尼难治性急性GVHD的工作定义,以区别于芦可替尼依赖,并给出追加治疗的临床指征和 eligibility 标准。
研究设计与样本
- 本文为立场论文,基于芦可替尼获批用于治疗成人和12岁及以上儿童患者糖皮质激素难治性急性GVHD的背景,提出新的工作定义。
主要发现
- 仅半数重度急性GVHD患者对一线糖皮质激素治疗有反应,数十年来糖皮质激素难治性急性GVHD缺乏最佳二线治疗。
- 芦可替尼近期获批用于成人和12岁及以上儿童患者糖皮质激素难治性急性GVHD的治疗。
关键数值与推荐
- 芦可替尼难治性急性GVHD定义为:芦可替尼治疗至少5至10天后,GVHD较基线进展,基于分期/分级客观增加或新器官受累。
- 芦可替尼难治性急性GVHD定义为:芦可替尼治疗≥14天后,GVHD较基线缺乏改善(部分缓解或更好)。
- 芦可替尼难治性急性GVHD定义为:初始改善后任何时间出现GVHD客观恶化(分期、分级增加或新器官受累)即失去反应。
- 患者出现≥3级治疗中出现且归因于芦可替尼的不良事件,停药7天内未缓解,且GVHD表现持续无改善,可作为追加治疗的临床指征。
- 芦可替尼治疗后第28天未达完全缓解或极好部分缓解,可考虑作为 eligibility 标准。
临床怎么用
- 作者提出上述工作定义用于界定芦可替尼难治性急性GVHD患者群体,以指导后续治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic stem cell transplantation. Only half of patients with severe acute GVHD respond to first-line treatment with corticosteroids and, for several decades, there was no optimal second-line treatment of patients with corticosteroid-refractory acute GVHD. Ruxolitinib was recently approved for the treatment of corticosteroid-refractory acute GVHD in adult and pediatric patients 12 years and older. Thus, it is important to define the patient population that would now be considered as refractory to ruxolitinib vs ruxolitinib dependent. Here, we propose to define ruxolitinib-refractory acute GVHD as disease that shows: (1) progression of GVHD compared with baseline after at least 5 to 10 days of treatment with ruxolitinib, based either on objective increase in stage/grade, or new organ involvement; (2) lack of improvement in GVHD (partial response or better) compared with baseline after ≥14 days of treatment with ruxolitinib; or (3) loss of response, defined as objective worsening of GVHD determined by increase in stage, grade, or new organ involvement at any time after initial improvement. GVHD manifestations that persist without improvement in patients who had a grade ≥3 treatment-emergent and ruxolitinib-attributed adverse event that did not resolve within 7 days of discontinuing ruxolitinib would serve as a clinical indication for additional treatment. In addition, absence of complete response or very good partial response at day 28 after ruxolitinib could be considered as an eligibility criterion.
引用
- Mohty M, Holler E, Jagasia M, et al. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood. 2020. PMID: 32756949. doi:10.1182/blood.2020007336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。